AMAL THERAPEUTICS

amal-therapeutics-logo

Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.

#People #Financial #Website #More

AMAL THERAPEUTICS

Social Links:

Industry:
Biopharma Biotechnology Life Science Neuroscience Therapeutics

Founded:
2012-01-01

Address:
Geneva, Geneve, Switzerland

Country:
Switzerland

Website Url:
http://www.amaltherapeutics.com

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
45.34 M USD

Technology used in webpage:
SPF Amazon Google Apps For Business Microsoft Azure DNS Facebook Sharer Facebook Domain Verification GlobalSign Domain Verification Incapsula Nameshield



Current Advisors List

hanna-kleczkowska_image

Hanna Kleczkowska Board Member @ Amal Therapeutics
Board_member

frank-kalkbrenner_image

Frank Kalkbrenner Board Member @ Amal Therapeutics
Board_member

knut-elbers_image

Knut Elbers Board Member @ Amal Therapeutics
Board_member

diego-braguglia_image

Diego Braguglia Member of the Board @ Amal Therapeutics
Board_member

andreas-wallnöfer_image

Andreas Wallnöfer Board Member @ Amal Therapeutics
Board_member

erwin-boos_image

Erwin Boos Board Observer @ Amal Therapeutics
Board_observer

Current Employees Featured

knut-elbers_image

Knut Elbers
Knut Elbers Director @ Amal Therapeutics
Director

madiha-derouazi_image

Madiha Derouazi
Madiha Derouazi Founder & CEO @ Amal Therapeutics
Founder & CEO

diego-braguglia_image

Diego Braguglia
Diego Braguglia Director @ Amal Therapeutics
Director

Founder


madiha-derouazi_image

Madiha Derouazi

Investors List

boehringer-ingelheim-venture-fund_image

Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund investment in Series B - Amal Therapeutics

high-tech-gründerfonds_image

High-Tech Grunderfonds

High-Tech Grunderfonds investment in Series B - Amal Therapeutics

biomedpartners_image

BioMedPartners

BioMedPartners investment in Series B - Amal Therapeutics

schroder-adveq_image

Schroder Adveq

Schroder Adveq investment in Series B - Amal Therapeutics

helsinn-investment-fund_image

3B Future Health Fund

3B Future Health Fund investment in Series B - Amal Therapeutics

vi-partners_image

VI Partners

VI Partners investment in Series B - Amal Therapeutics

high-tech-gründerfonds_image

High-Tech Grunderfonds

High-Tech Grunderfonds investment in Series B - Amal Therapeutics

schroder-adveq_image

Schroder Adveq

Schroder Adveq investment in Series B - Amal Therapeutics

biomedpartners_image

BioMedPartners

BioMedPartners investment in Series B - Amal Therapeutics

helsinn-investment-fund_image

3B Future Health Fund

3B Future Health Fund investment in Series B - Amal Therapeutics

Official Site Inspections

http://www.amaltherapeutics.com

  • Host name: 45.60.65.30
  • IP address: 45.60.65.30
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Amal Therapeutics"

amaltherapeutics.com - Transforming the prospects of cancer …

Oct 20, 2022 Harnessing the power of KISIMA® immunisation technology to discover and develop therapeutic vaccinesSee details»

Leadership Team - Amal Therapeutics - amaltherapeutics.com

AMAL Therapeutics is led by a dedicated team with a strong background in molecular and cellular biotechnology R&D gained from working within start-ups, at renowned Academic Institutes, as …See details»

Amal Therapeutics - Crunchbase Company Profile & Funding

Contact Email [email protected] Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal …See details»

BI Acquires AMAL Therapeutics | Boehringer Ingelheim US

Tel: +44 (0) 207 457 2020 [email protected]. Media Contacts. Linda Ruckel 900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877. Phone +1 (203) 791-6672. …See details»

Amal Therapeutics SA – Swiss Biotech

[email protected]; Location. Avenue de la Roseraie 64, 1205 Genève, Switzerland. Get Directions Canton. Geneva; Facts & figures. Type of organization. Private company. Year …See details»

Amal Therapeutics Company Profile 2024: Valuation, …

Amal Therapeutics General Information Description. Developer of therapeutic vaccines designed to facilitate oncology treatment. The company's peptide-based vaccines generate a cellular immune response including activation of killer T …See details»

Amal Therapeutics - LIVE

AMAL Therapeutics (AMAL) is a biotech, developing unique therapeutic vaccines and a distinct unit of the Discovery Research organization of the Boehringer Ingelheim group of companies. …See details»

Amal Therapeutics - VentureRadar

"AMAL Therapeutics (AMAL) is a pre-clinical stage Swiss biotech, developing unique therapeutic vaccines. Our aim is to overcome the challenges around effective anti-cancer therapy by …See details»

Amal Therapeutics SA - Genf, Switzerland - bionity.com

Amaltherapeutics.com. Contact. Profile Products News. Contact. About Amal Therapeutics. Amal Therapeutics SA is a privately held Swiss biotech start-up company and a spin-off from the …See details»

AMAL Therapeutics - Overview, News & Similar companies

Jul 15, 2019 AMAL Therapeutics contact info: Phone number: +41 223794688 Website: www.amaltherapeutics.com What does AMAL Therapeutics do? AMAL Therapeutics SA is a …See details»

Amal Therapeutics Company Overview, Contact Details

[email protected]: 45%. See more formats. Frequently Asked Questions Where is Amal Therapeutics 's headquarters located? Amal Therapeutics 's main headquarters is …See details»

Amal Therapeutics - Craft

Amal Therapeutics is a biotech company, which engages in the research and development of therapeutic vaccines in oncology. The Company uses its cell penetrating peptide platform to …See details»

AMAL Therapeutics - Association GEnevoise pour les Métiers de …

Technology Platform. AMAL Therapeutics developed a versatile and flexible recombinant protein vaccine technology platform called KISIMA Ò.KISIMA is a three-component chimeric protein …See details»

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly ...

Jul 15, 2019 Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform. Ingelheim am Rhein, …See details»

☑️Amal Therapeutics — Consulting Organization from …

Dec 6, 2024 Amal Therapeutics — Consulting Organization from Switzerland, has experience with European Commission Directorate-General for International Partnerships (EuropeAid …See details»

Amal Therapeutics SA - Venturelab

Mar 9, 2012 Amal Therapeutics SA : Amal Therapeutics SA, a spin-off from the University of Geneva, is developing new cancer vaccines, using with a proprietary family of vectors.See details»

Amal Therapeutics SA - startup.ch

Amal Therapeutics SA : Amal Therapeutics SA, a spin-off from the University of Geneva, is developing new cancer vaccines, using with a proprietary family of vectors.See details»

AMAL Therapeutics to publish research outcomes in Cancers

AMAL Therapeutics to publish research outcomes in Cancers. Geneva, Switzerland, October 20, 2022 – AMAL Therapeutics announced today that the latest findings of its research team is on …See details»

News - amaltherapeutics.com

Geneva, Switzerland, August 31, 2021 - AMAL Therapeutics announced today that the latest findings of its in vivo research team, in collaboration with Prof. Guido Wollman’s lab at the …See details»

linkstock.net © 2022. All rights reserved